Vulnerability to infections and secondary immunodeficiencies in patients with non-Hodgkin's lymphomas starting anti-CD20 antibody containing therapies - PubMed
4 days ago
- #Non-Hodgkin's Lymphoma
- #Immunodeficiency
- #Anti-CD20 Therapy
- Limited data exists on immune status and infection vulnerability in NHL patients undergoing anti-CD20 antibody therapies (CD20CT).
- A multicentre study of 101 NHL patients in Germany tracked infections, hospitalizations, and immune status over one year post-CD20CT initiation.
- Key findings include a significant drop in CD4 T-cell counts post-therapy (1,048.9/µl to 459.7/µl) and a non-significant decrease in IgG levels.
- Infection rates increased significantly post-therapy (3.15 to 7.00 infections per 1,000 days).
- Immune monitoring was performed in only 21% of patients for CD4 cells and 22% for IgG levels.
- 8 patients died during the study, with infections/sepsis accounting for 3 deaths.